India – Hyderabad-based pharmaceutical firm Bharat Biotech shall be pushing to create a new locally made COVID-19 virus vaccination where an unspecified number of volunteers shall be vaccinated in an effort to immunize them from the pandemic virus with hopes of giving insight on how to stop the spreading viral infections.
120 vaccine programs are currently running around the world with 6-7 of them developing within India as trials around the world push to take the successful testing in animals to the next level. The animal tests have offered that the results are safe and are triggering a response in the immune system.
An isolated strain was used to start the development within Bharat Biotech with the first India-made vaccines considering they had played leading hands in creating vaccines for such viruses as polio,pneumonia, rotavirus, measles, mumps and rubella and other viral diseases, boasting that they had utilized stringent lab tests on the strain of virus to point of weakening it under the conditions of their laboratories.
A test to check whether the vaccine is safe shall be conducted among two trials to also test the efficacy of the viral weakener. Bharat Biotech utilized the locally obtained strain to strong effect as the vaccine is developing rather quickly thanks to the instrumental data gathered during these tests.
“The difference between the strains present globally is something still being researched,” Bharat Biotech’s spokesperson explained to the BBC.
Bharat Biotech is calling the new vaccine Covaxin which was developed in collaboration with the Indian Council of Medical Research as well as India’s National Institute of Virology, playing the words of “COVID-Vaccine” into a catchy brand name.
The famous vaccine making company had been pivotal in delivering more than 4 billion doses of vaccines in world wide operations for such strains as the H1N1 and rotavirus among others.
Experts believe that the anti-COVID-19 vaccines will hit the market sometime in the middle of 2021, marking it around 12-18 months after the virus first came into view as the infamous Sars-Cov2 strain.
Three other pharmaceutical companies took to the race as well, securing their own local strain of the COVID-19 virus to create their own vaccines to counteract the monopoly that Covaxion would stir in the market.
The word among immunologists however is it would be a huge feat if the vaccines work but they still can not see any guarantees enough to back these advances fully.
